Hydroxychloroquine: A multifaceted treatment in lupus

Presse Medicale

Volumn 43, Issue 6P2, 2014, Pages

  Costedoat Chalumeau, Nathalie ^a   Dunogué, Bertrand ^a   Morel, Nathalie ^a   Le Guern, Véronique ^a   Guettrot Imbert, Gaëlle ^b  

^a AP HP université René Descartes Paris V HÔpital Cochin Centre de référence maladies auto immunes Systémiques rares pÔle médecine service de médecine interne ^*  (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DOXYCYCLINE; HYDROXYCHLOROQUINE; PLACEBO; ALPHA INTERFERON; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LUPUS ANTICOAGULANT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; RO ANTIBODY; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

BLOOD TOXICITY; BONE DENSITY; BREAST FEEDING; CANCER SURVIVAL; CARDIOTOXICITY; CONGENITAL HEART BLOCK; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DYSLIPIDEMIA; EYE TOXICITY; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLYCEMIC CONTROL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE LIPODYSTROPHY; KIDNEY FAILURE; LUPUS VULGARIS; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NONHUMAN; PATIENT COMPLIANCE; PIGMENT DISORDER; PREGNANCY; PRESCRIPTION; PROPHYLAXIS; PRURITUS; PSORIASIS; Q FEVER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DISEASE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT SURVEY; SKIN ALLERGY; SKIN TOXICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT REFUSAL; ABDOMINAL DISTENSION; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADJUVANT THERAPY; AGRANULOCYTOSIS; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; APLASTIC ANEMIA; ATHEROSCLEROSIS; ATRIOVENTRICULAR BLOCK; BLURRED VISION; CANCER PREVENTION; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG MILK LEVEL; DRUG WITHDRAWAL; ECCHYMOSIS; ECZEMA; ERYTHEMA ANNULARE CENTRIFUGUM; ERYTHRODERMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING IMPAIRMENT; HEART BUNDLE BRANCH BLOCK; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEARTBURN; HYPERPIGMENTATION; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; HYPOPIGMENTATION; INTERFERON PRODUCTION; IRRITABILITY; LONG TERM SURVIVAL; LUPUS ERYTHEMATOSUS NEPHRITIS; MACULAR EDEMA; MEASLES LIKE RASH; MEDICATION COMPLIANCE; MYASTHENIA LIKE SYNDROME; MYOPATHY; NAUSEA; NERVOUSNESS; NEUROPATHY; NIGHT BLINDNESS; NIGHTMARE; PARESIS; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; PLASMACYTOID DENDRITIC CELL; PRIMARY PREVENTION; PSYCHOSIS; REMISSION; RESPIRATORY FAILURE; RETINA MACULOPATHY; RETINOPATHY; RHEUMATOID ARTHRITIS; SCOTOMA; SEIZURE; SKIN BRUISING; SKIN MANIFESTATION; THROMBOSIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VISUAL IMPAIRMENT; VOMITING;

ANTIMALARIALS; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; HALF-LIFE; HUMANS; HYDROXYCHLOROQUINE; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDICATION ADHERENCE; RETINAL DISEASES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 84902547534     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.03.007     Document Type: Short Survey

References (149)

1. Costedoat-Chalumeau N., Leroux G., Piette J.C., Amoura Z. Antimalarials and systemic lupus erythematosus. Systemic lupus erythematosus 2010, 1061-1081. Elsevier, Paris. 5th edition. R.G. Lahita, G. Tsokos, J.P. Buyon, T. Koike (Eds.).
2. Ziegler H.K., Unanue E.R. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A 1982, 79:175-178.
3. Sperber K., Quraishi H., Kalb T.H., Panja A., Stecher V., Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 1993, 20:803-808.
4. Gilman A.L., Beams F., Tefft M., Mazumder A. The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease. Bone Marrow Transplant 1996, 17:1069-1075.
5. Goldman F.D., Gilman A.L., Hollenback C., Kato R.M., Premack B.A., Rawlings D.J. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000, 95:3460-3466.
6. Landewe R.B., Miltenburg A.M., Verdonk M.J., Verweij C.L., Breedveld F.C., Daha M.R., et al. Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Clin Exp Immunol 1995, 102:144-151.
7. Schultz K.R., Bader S., Nelson D., Wang M.D., HayGlass K.T. Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist?. Transplantation 1997, 64:1055-1065.
8. Potvin F., Petitclerc E., Marceau F., Poubelle P.E. Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. J Immunol 1997, 158:1872-1879.
9. Picot S., Peyron F., Vuillez J.P., Polack B., Ambroise-Thomas P. Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro. J Infect Dis 1991, 164:830.
10. Namiuchi S., Kumagai S., Imura H., Suginoshita T., Hattori T., Hirata F. Quinacrine inhibits the primary but not secondary proliferative response of human cytotoxic T cells to allogeneic non-T cell antigens. J Immunol 1984, 132:1456-1461.
11. van den Borne B.E., Dijkmans B.A., de Rooij H.H., le Cessie S., Verweij C.L. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 1997, 24:55-60.
12. Tishler M., Yaron I., Shirazi I., Yaron M. Hydroxychloroquine treatment for primary Sjogren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 1999, 58:253-256.
13. Bondeson J., Sundler R. Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmacol 1998, 30:357-366.
14. da Silva J.C., Mariz H.A., da Rocha L.F., de Oliveira P.S., Dantas A.T., Duarte A.L., et al. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics 2013, 68:766-771.
15. Sacre K., Criswell L.A., McCune J.M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012, 14:R155.
16. Willis R., Seif A.M., McGwin G., Martinez-Martinez L.A., Gonzalez E.B., Dang N., et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 2012, 21:830-835.
17. Boya P., Gonzalez-Polo R.A., Poncet D., Andreau K., Vieira H.L., Roumier T., et al. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 2003, 22:3927-3936.
18. Lagneaux L., Delforge A., Dejeneffe M., Massy M., Bernier M., Bron D. Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio. Leuk Lymphoma 2002, 43:1087-1095.
19. Lai J.H., Ho L.J., Lu K.C., Chang D.M., Shaio M.F., Han S.H. Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J Immunol 2001, 166:6914-6924.
20. Meng X.W., Feller J.M., Ziegler J.B., Pittman S.M., Ireland C.M. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum 1997, 40:927-935.
21. Kim W.U., Yoo S.A., Min S.Y., Park S.H., Koh H.S., Song S.W., et al. Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. Clin Exp Immunol 2006, 144:503-511.
22. Liu S.T., Wang C.R., Yin G.D., Liu M.F., Lee G.L., Chen M.Y., et al. Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 2001, 19:29-35.
23. Cohen S.N., Yielding K.L. Inhibition of DNA and RNA polymerase reactions by chloroquine. Proc Natl Acad Sci U S A 1965, 54:521-527.
24. Filippov A., Skatova G., Porotikov V., Kobrinsky E., Saxon M. Ca2+-antagonistic properties of phospholipase A2 inhibitors, mepacrine and chloroquine. Gen Physiol Biophys 1989, 8:113-118.
25. Lafyatis R., York M., Marshak-Rothstein A. Antimalarial agents: Closing the gate on toll-like receptors?. Arthritis Rheum 2006, 54:3068-3070.
26. Brentano F., Schorr O., Gay R.E., Gay S., Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005, 52:2656-2665.
27. Kyburz D., Brentano F., Gay S. Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2006, 2:458-459.
28. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603-607.
29. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., Hammoud H.A., Aymard G., Cacoub P., et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54:3284-3290.
30. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991, 324:150-154. The Canadian Hydroxychloroquine Study Group.
31. Tsakonas E., Joseph L., Esdaile J.M., Choquette D., Senecal J.L., Cividino A., et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998, 7:80-85.
32. Levy R.A., Vilela V.S., Cataldo M.J., Ramos R.C., Duarte J.L., Tura B.R., et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001, 10:401-404.
33. Meinao I.M., Sato E.I., Andrade L.E., Ferraz M.B., Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996, 5:237-241.
34. Fangtham M., Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep 2013, 15:360.
35. Petri M., Alarcon G.S., Kimberly R.P., Reveille J.D. Predictors of renal insufficiency in systemic lupus erythematosus (abstract). Arthritis Rheum 2005.
36. Kasitanon N., Fine D.M., Haas M., Magder L.S., Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006, 15:366-370.
37. Pons-Estel G.J., Alarcon G.S., McGwin G., Danila M.I., Zhang J., Bastian H.M., et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009, 61:830-839.
38. Hahn B.H., McMahon M.A., Wilkinson A., Wallace W.D., Daikh D.I., Fitzgerald J.D., et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012, 64:797-808.
39. Bertsias G.K., Tektonidou M., Amoura Z., Aringer M., Bajema I., Berden J.H., et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012, 71:1771-1782.
40. James J.A., Kim-Howard X.R., Bruner B.F., Jonsson M.K., McClain M.T., Arbuckle M.R., et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007, 16:401-409.
41. Edwards M.H., Pierangeli S., Liu X., Barker J.H., Anderson G., Harris E.N. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997, 96:4380-4384.
42. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996, 25:191-193.
43. Mok M.Y., Chan E.Y., Fong D.Y., Leung K.F., Wong W.S., Lau C.S. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol 2005, 32:622-628.
44. Ruiz-Irastorza G., Egurbide M.V., Pijoan J.I., Garmendia M., Villar I., Martinez-Berriotxoa A., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006, 15:577-583.
45. Ho K.T., Ahn C.W., Alarcon G.S., Baethge B.A., Tan F.K., Roseman J., et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005, 44:1303-1307.
46. Tektonidou M.G., Laskari K., Panagiotakos D.B., Moutsopoulos H.M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009, 61:29-36.
47. Kaiser R., Cleveland C.M., Criswell L.A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009, 68:238-241.
48. Jung H., Bobba R., Su J., Shariati-Sarabi Z., Gladman D.D., Urowitz M., et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010, 62:863-868.
49. Broder A., Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol 2013, 40:30-33.
50. Erkan D., Lockshin M.D. APS ACTION-Antiphospholipid syndrome alliance for clinical trials and international networking. Lupus 2012, 21:695-698.
51. Rand J.H., Wu X.X., Quinn A.S., Chen P.P., Hathcock J.J., Taatjes D.J. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008, 112:1687-1695.
52. Shojania K., Koehler B.E., Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol 1999, 26:195-196.
53. Quatraro A., Consoli G., Magno M., Caretta F., Nardozza A., Ceriello A., et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?. Ann Intern Med 1990, 112:678-681.
54. Wasko M.C., Hubert H.B., Lingala V.B., Elliott J.R., Luggen M.E., Fries J.F., et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007, 298:187-193.
55. Penn S.K., Kao A.H., Schott L.L., Elliott J.R., Toledo F.G., Kuller L., et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2010, 37:1136-1142.
56. Solomon D.H., Massarotti E., Garg R., Liu J., Canning C., Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011, 305:2525-2531.
57. Rahman P., Gladman D.D., Urowitz M.B., Yuen K., Hallett D., Bruce I.N. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999, 26:325-330.
58. Petri M., Lakatta C., Magder L., Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96:254-259.
59. Hodis H.N., Quismorio F.P., Wickham E., Blankenhorn D.H. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993, 20:661-665.
60. Wallace D.J., Metzger A.L., Stecher V.J., Turnbull B.A., Kern P.A. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990, 89:322-326.
61. Munro R., Morrison E., McDonald A.G., Hunter J.A., Madhok R., Capell H.A. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997, 56:374-377.
62. Cairoli E., Rebella M., Danese N., Garra V., Borba E.F. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 2012, 21:1178-1182.
63. Tam L.S., Li E.K., Lam C.W., Tomlinson B. Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Lupus 2000, 9:413-416.
64. Borba E.F., Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001, 28:780-785.
65. Beynen A.C., van der Molen A.J., Geelen M.J. Inhibition of hepatic cholesterol biosynthesis by chloroquine. Lipids 1981, 16:472-474.
66. Pagler T.A., Neuhofer A., Laggner H., Strobl W., Stangl H. Cholesterol efflux via HDL resecretion occurs when cholesterol transport out of the lysosome is impaired. J Lipid Res 2007, 48:2141-2150.
67. Sachet J.C., Borba E.F., Bonfa E., Vinagre C.G., Silva V.M., Maranhao R.C. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007, 16:273-278.
68. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.
69. Mok C.C., Mak A., Ma K.M. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 2005, 14:106-112.
70. Lakshminarayanan S., Walsh S., Mohanraj M., Rothfield N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 2001, 28:102-108.
71. Jacobs J., Korswagen L.A., Schilder A.M., van Tuyl L.H., Dijkmans B.A., Lems W.F., et al. Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporos Int 2013, 24:1827-1833.
72. Sotelo J., Briceno E., Lopez-Gonzalez M.A. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006, 144:337-343.
73. Rahim R., Strobl J.S. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 2009, 20:736-745.
74. Ruiz-Irastorza G., Ugarte A., Egurbide M.V., Garmendia M., Pijoan J.I., Martinez-Berriotxoa A., et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007, 66:815-817.
75. Fedson D.S. Confronting an influenza pandemic with inexpensive generic agents: can it be done?. Lancet Infect Dis 2008, 8:571-576.
76. Rolain J.M., Colson P., Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007, 30:297-308.
77. Lagier J.C., Fenollar F., Lepidi H., Giorgi R., Million M., Raoult D. Treatment of classic Whipple's disease: from in vitro results to clinical outcome. J Antimicrob Chemother 2014, 69:219-227.
78. Paton N.I., Goodall R.L., Dunn D.T., Franzen S., Collaco-Moraes Y., Gazzard B.G., et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012, 308:353-361.
79. Molad Y., Gorshtein A., Wysenbeek A.J., Guedj D., Majadla R., Weinberger A., et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 2002, 11:356-361.
80. Fessler B.J., Alarcon G.S., McGwin G., Roseman J., Bastian H.M., Friedman A.W., et al. Systemic lupus erythematosus in three ethnic grups: XVI. Assciation of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005, 52:1473-1480.
81. Akhavan P.S., Su J., Lou W., Gladman D.D., Urowitz M.B., Fortin P.R. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 2013, 40:831-841.
82. Pons-Estel G.J., Alarcon G.S., Gonzalez L.A., Zhang J., Vila L.M., Reveille J.D., et al. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res (Hoboken) 2010, 62:393-400.
83. Petri M., Purvey S., Fang H., Magder L.S. Predictors of organ damage in systemic lupus erythematosus: the Hopkins lupus cohort. Arthritis Rheum 2012, 64:4021-4028.
84. Alarcon G.S., McGwin G., Bertoli A.M., Fessler B.J., Calvo-Alen J., Bastian H.M., et al. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. data from lumina, a multiethnic us cohort (LUMINAL). Ann Rheum Dis 2007, 66:1168-1172.
85. Shinjo S.K., Bonfa E., Wojdyla D., Borba E.F., Ramirez L.A., Scherbarth H.R., et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010, 62:855-862.
86. Zheng Z.H., Zhang L.J., Liu W.X., Lei Y.S., Xing G.L., Zhang J.J., et al. Predictors of survival in Chinese patients with lupus nephritis. Lupus 2012, 21:1049-1056.
87. Costedoat-Chalumeau N., Izmirly P., Wahren-Herlenius M., Silverman E., Brucato A., Boutjdir M., et al. Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials." by Gleicher N, Elkayam U. Autoimmun Rev 2013, 12:1039-1045.
88. Izmirly P.M., Kim M.Y., Llanos C., Le P.U., Guerra M.M., Askanase A.D., et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010, 69:1827-1830.
89. Izmirly P.M., Costedoat-Chalumeau N., Pisoni C.N., Khamashta M.A., Kim M.Y., Saxena A., et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012, 126:76-82.
90. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69:20-28.
91. Jimenez-Alonso J., Tercedor J., Jaimez L., Garcia-Lora E. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus. Arthritis Rheum 1998, 41:744-745.
92. Physician's Desk Reference. http://www.pdr.net; 2013. [Access 31/03/2014).
93. Jallouli M., Frances C., Piette J.C., Huong D.L., Moguelet P., Factor C., et al. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. JAMA Dermatol 2013, 149:935-940.
94. Avina-Zubieta J.A., Galindo-Rodriguez G., Newman S., Suarez-Almazor M.E., Russell A.S. Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 1998, 57:582-587.
95. Marmor M.F. New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum 2003, 48:1764.
96. Levy G.D., Munz S.J., Paschal J., Cohen H.B., Pince K.J., Peterson T. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997, 40:1482-1486.
97. Marmor M.F., Kellner U., Lai T.Y., Lyons J.S., Mieler W.F. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011, 118:415-422.
98. Costedoat-Chalumeau N., Hulot J.S., Amoura Z., Delcourt A., Maisonobe T., Dorent R., et al. Cardiomyopathy related to antimalarial therapy with Iillustrative case report. Cardiology 2006, 107:73-80.
99. Stein M., Bell M.J., Ang L.C. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000, 27:2927-2931.
100. Sghirlanzoni A., Mantegazza R., Mora M., Pareyson D., Cornelio F. Chloroquine myopathy and myasthenia-like syndrome. Muscle Nerve 1988, 11:114-119.
101. Siddiqui A.K., Huberfeld S.I., Weidenheim K.M., Einberg K.R., Efferen L.S. Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest 2007, 131:588-590.
102. Munster T., Gibbs J.P., Shen D., Baethge B.A., Botstein G.R., Caldwell J., et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:1460-1469.
103. Puri P.K., Lountzis N.I., Tyler W., Ferringer T. Hydroxychloroquine-induced hyperpigmentation: the staining pattern. J Cutan Pathol 2008, 35:1134-1137.
104. Meller S., Gerber P.A., Homey B. Clinical image: blonde by prescription. Arthritis Rheum 2008, 58:2286.
105. Gul U., Cakmak S.K., Kilic A., Gonul M., Bilgili S. A case of hydroxychloroquine induced pruritus. Eur J Dermatol 2006, 16:586-587.
106. Wolf R., Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999, 455:221-225.
107. Herman S.M., Shin M.H., Holbrook A., Rosenthal D. The role of antimalarials in the exacerbation of psoriasis: a systematic review. Am J Clin Dermatol 2006, 7:249-257.
108. Kalia S., Dutz J.P. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007, 20:160-174.
109. Mates M., Zevin S., Breuer G.S., Navon P., Nesher G. Desensitization to hydroxychloroquine-experience of 4 patients. J Rheumatol 2006, 33:814-816.
110. Donado C.D., Diez E.M. Successful desensitization for hydroxychloroquine anaphylaxis. J Rheumatol 2010, 37:1975-1976.
111. Chernof D., Taylor K.S. Hydroxychloroquine-induced agranulocytosis. Arch Dermatol 1968, 97:163-164.
112. Propp R.P., Stillman J.S. Agranulocytosis and hydroxychloroquine. N Engl J Med 1967, 277:492-493.
113. Costedoat-Chalumeau N., Amoura Z., Aymard G., Le T.H., Wechsler B., Vauthier D., et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 2002, 46:1123-1124.
114. Parke A., West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996, 23:1715-1718.
115. Buchanan N.M., Toubi E., Khamashta M.A., Lima F., Kerslake S., Hughes G.R. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996, 55:486-488.
116. Motta M., Tincani A., Faden D., Zinzini E., Chirico G. Antimalarial agents in pregnancy. Lancet 2002, 359:524-525.
117. Klinger G., Morad Y., Westall C.A., Laskin C., Spitzer K.A., Koren G., et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001, 358:813-814.
118. Clowse M.E., Magder L., Witter F., Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006, 54:3640-3647.
119. Costedoat-Chalumeau N., Amoura Z., Duhaut P., Huong du L.T., Sebbough D., Wechsler B., et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003, 48:3207-3211.
120. Sperber K., Hom C., Chao C.P., Shapiro D., Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol 2009, 7:9.
121. Diav-Citrin O., Blyakhman S., Shechtman S., Ornoy A. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol 2013, 39C:58-62.
122. Cimaz R., Brucato A., Meregalli E., Muscara M., Sergi P. Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al. Arthritis Rheum 2004, 50:3056-3057. [author reply 7-8].
123. Costedoat-Chalumeau N., Amoura Z., Sebbough D., Piette J.C. Reply. Arthritis Rheum 2004, 50:3057.
124. Motta M., Tincani A., Faden D., Zinzini E., Lojacono A., Marchesi A., et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2004, 14:14.
125. Renault F., Flores-Guevara R., Renaud C., Richard P., Vermersch A.I., Gold F. Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatr 2009, 98:1500-1503.
126. Ingster-Moati I., Albuisson E. Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatr 2010, 99:4. [author reply-5].
127. Osadchy A., Ratnapalan T., Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol 2011, 38:2504-2508.
128. Nation R.L., Hackett L.P., Dusci L.J., Ilett K.F. Excretion of hydroxychloroquine in human milk. Br J Clin Pharmacol 1984, 17:368-369.
129. Ostensen M., Khamashta M., Lockshin M., Parke A., Brucato A., Carp H., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006, 8:209.
130. Micromedex® Healthcare Series; http://www.thomsonhc.com/hcs/librarian; 2013. [Access 2013].
131. Jallouli M., Saadoun D., Eymard B., Leroux G., Haroche J., Le Thi Huong D., et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol 2012, 259:1290-1297.
132. Harper P., Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol 2007, 10:444-455.
133. Singal A.K., Kormos-Hallberg C., Lee C., Sadagoparamanujam V.M., Grady J.J., Freeman D.H., et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol 2012, 10:1402-1409.
134. Costedoat-Chalumeau N., Pouchot J., Guettrot-Imbert G., Le Guern V., Leroux G., Marra D., et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013, 27:329-340.
135. Carmichael S.J., Day R.O., Tett S.E. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. Intern Med J 2013, 43:547-553.
136. Tett S.E., Day R.O., Cutler D.J. Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis--a cross sectional study. J Rheumatol 1993, 20:1874-1879.
137. Tett S.E., Cutler D.J., Beck C., Day R.O. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis--a prospective, dose ranging study. J Rheumatol 2000, 27:1656-1660.
138. Costedoat-Chalumeau N., Galicier L., Aumaitre O., Frances C., Le Guern V., Liote F., et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 2013, 72:1786-1792.
139. Frances C., Cosnes A., Duhaut P., Zahr N., Soutou B., Ingen-Housz-Oro S., et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012, 148:479-484.
140. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., Aymard G., Leroux G., Hammoud H.A., et al. Very low blood Hydroxychloroquine concentrations as an objective marker of poor adherence to treatment in systemic lupus erythematosus. Ann Rheum Dis 2007, 66:821-824.
141. Ting T.V., Kudalkar D., Nelson S., Cortina S., Pendl J., Budhani S., et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol 2012, 39:174-179.
142. Petri M., Fand H., Clarke W. Hydroxychloroquine levels identify four distinct subsets of systemic lupus erythematosus patients (abstract). Arthritis Rheum 2013, 65:S770.
143. Smith E.R., Klein-Schwartz W. Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med 2005, 28:437-443.
144. Ruiz-Irastorza G., Khamashta M.A. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 2008, 17:271-273.
145. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011, 13:77-80.
146. Schmajuk G., Yazdany J., Trupin L., Yelin E. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010, 62:386-392.
147. Navarra S.V., Guzman R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
148. Wallace D.J., Kalunian K., Petri M.A., Strand V., Houssiau F.A., Pike M., et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014, 73:183-190.
149. Zimmer R., Scherbarth H.R., Rillo O.L., Gomez-Reino J.J., Muller S. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 2013, 72:1830-1835.